Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes

Patent metadata

Field	Value
Publication number	US-9630976-B2
Application number	US-201314412564-A
Country	US
Kind code	B2
Filing date	Jul 2, 2013
Priority date	Jul 3, 2012
Publication date	Apr 25, 2017
Grant date	Apr 25, 2017

Abstract

Provision of orally-available and low-toxic somatostatin receptor subtype 2 agonist. Since the compound represented by the general formula (I):

[wherein all symbols represent the same meanings as those described in the description] a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof is non-peptidic low-molecular compound which has strong somatostatin receptor subtype 2 agonist activity, the compound is orally-available. Additionally, since the compound is low-toxic, the compound is useful for the prevention and/or treatment of the somatostatin related diseases such as acromegaly or gastrointestinal obstruction.

First claim

The invention claimed is:

1. A compound of general formula (I):

wherein
R 1 is (1) halogen, (2) hydroxyl, (3) C1-4 alkyl which may be substituted with substituents selected from the group consisting of (a) —OR 7 and (b) halogen, (4) C1-4 alkoxy, or (5) C3-8 cycloalkyl;
p is an integer of 0 to 3; when p is 2 or more, each R 1 may be the same or different;
R 2 is (1) halogen, (2) oxo, (3) —OR 3 , (4) —COR 4 , (5) —COOR 5 , (6) —SO 2 R 6 , (7) C1-4 alkyl which may be substituted with substituents selected from the group consisting of (a) —OR 7 , (b) —COR 8 , (c) —COOR 9 , (d) —SO 2 R 10 , (e) halogen, and (f) cyano, (8) C3-6 monocyclic carbon ring which may be substituted with substituents selected from the group consisting of (a) C1-4 alkyl, (b) phenyl, and (c) hydroxymethyl, (9) 5 to 6 membered monocyclic hetero ring which may be substituted with substituents selected from the group consisting of (a) C1-4 alkyl, (b) phenyl, and (c) hydroxymethyl, (10) —NR 76 R 77 , (11) —CONR 78 R 79 , (12) —NR 80 COR 81 or (13) cyano;
R 3 and R 7 are independently (1) hydrogen, (2) C1-4 alkyl, (3) C1-4 haloalkyl, or (4) —COR 4 ;
R 4 and R 8 are independently C1-4 alkyl or amino;
R 5 , R 6 , R 9 and R 10 are independently hydrogen or C1-4 alkyl;
R 76 to R 81 are independently hydrogen or C1-4 alkyl;
q is an integer of 0 to 3; when q is 2 or more, more than one R 2 may be same or different;
Ring A is benzene, benzimidazole, indazole, indole, imidazole, triazole, pyrazole, pyridine, pyrimidine, thiophene, oxazole, thiazole, or oxadiazole;
Ring G is benzene;
L is (1) bond, (2) —CR 21 ═CR 22 →, (3) —X→, (4) —X—CR 23 R 24 →, (5) —CR 25 R 26 —X→, (6) —X—CR 27 R 28 —O→, (7) —X—O—CR 29 R 30 →, (8) —O—CR 31 R 32 —X→, or (9) —CR 33 R 34 —O—X→(wherein the arrow is a binding position in each group);
R 21 to R 34 are independently hydrogen or C1-4 alkyl;
X is (1) —O—, (2) —C(═O)—, (3) —NR 41 —, (4) —C(═O)—NR 42 —, or (5) —NR 43 —C(═O)—;
R 41 to R 43 are independently hydrogen or C1-4 alkyl;
M is a bond;
Z is piperidine which may be substituted with a substituent selected from the group consisting of (a) halogen, (b) —NR 53 R 54 , (c) —OR 55 , (d) C1-4 alkyl which may be substituted with —NR 56 R 57 and/or —OR 58 , and (e) oxo;
R 53 to R 58 represent independently hydrogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 acyl, —C(═O)—O—(C1-4 alkyl), —C(═O)—OCH 2 R 68 , oxetanyl, or oxolanyl;
a salt thereof, an N-oxide thereof, or a solvate thereof.

2. The compound according to claim 1 , wherein the compound is
(1) 1-{3-(3,5-dimethylphenyl)-5-[4-(trifluoromethyl)phenyl]-4-pyridinyl}-4-piperidinamine,
(2) 1-{3-(3-fluoro-5-methylphenyl)-5-[4-(trifluoromethyl)phenyl]-4-pyridinyl}-4-piperidinamine,
(3) 3-{(E)-2-[4-(4-amino-1-piperidinyl)-5-(3-fluoro-5-methylphenyl)-3-pyridinyl]vinyl}benzonitrile,
(4) 4-(4-amino-1-piperidinyl)-N,5-bis(3,5-dimethyphenyl)pyridine-3-carboxamide,
(5) 1-[3-(4,6-dimethyl-1H-benzimidazol-2-yl)-5-(3,5-dimethyphenyl)-4-pyridyl]piperidin-4-amine,
(6) 1-[3-(4,6-dimethyl-1H-benzimidazol-2-yl)-5-(3,5-dimethyphenyl)-4-pyridinyl]-N-(3-oxetanyl)-4-piperidinamine,
(7) 1-[3-(3,5-dimethoxyphenyl)-5-(5,7-dimethyl-1H-benzimidazol-2-yl)-4-pyridinyl]-N-(2-fluoroethyl)-4-piperidinamine,
(8) 1-[3-(3-fluoro-5-methoxyphenyl)-5-(1H-indazol-6-yl)-4-pyridinyl]-4-piperidinamine,
(9) 5-[4-(4-amino-1-piperidinyl)-5-(3-fluoro-5-methylphenyl)-3-pyridinyl]-2-methylphenol,
(10) 1-[3-(5-chloro-1H-benzimidazol-2-yl)-5-(3-fluoro-5-methylphenyl)-4-pyridinyl]-N-(3-oxetanyl)-4-piperidinamine,
(11) (3-{4-(4-amino-1-piperidinyl)-5-[4-(trifluoromethyl)phenyl]-3-pyridinyl}-5-fluorophenyl)methanol, or
(12) {4-[4-(4-amino-1-piperidinyl)-5-(3-fluoro-5-methylphenyl)-3-pyridinyl]phenyl} acetonitrile.

3. The compound according to claim 1 , wherein the compound is
(1) rac-(3R,4S)-4-amino-1-[3-(3,5-dimethoxyphenyl)-5-(4,6-dimethyl-1H-benzimidazol-2-yl)-4-pyridinyl]-3-piperidinol, or
(2) rac-(3R,4S)-4-amino-1-[3-(6-fluoro-1H-benzimidazol-2-yl)-5-(3-fluoro-5-methoxyphenyl)-4-pyridinyl]-3-piperidinol.

4. A pharmaceutical composition which comprises the compound of the general formula (I) according to claim 1 , a salt thereof, an N-oxide thereof, or a solvate thereof and a pharmaceutically acceptable excipient.

5. A medicine comprising the compound according to claim 1 , a salt thereof, an N-oxide thereof, or a solvate thereof and at least one drug selected from the group consisting of pegvisomant, bromocriptine, and cabergoline.

6. A medicine comprising the compound according to claim 1 , a salt thereof, an N-oxide thereof, or a solvate thereof and at least one drug selected from the group consisting of prochlorperazine, levomepromazine, risperidone, metoclopramide, domperidone, diphenhydramine, chlorpheniramine, dimenhydrinate, promethazine, diprophylline, famotidine, cimetidine, scopolamine, tropisetron, granisetron, ondansetron, azasetron, ramosetron, indisetron, palonosetron, cisapride, mosapride, dexamethasone, betamethasone, prednisolone, aprepitant, olanzapine, quetiapine, perospirone, methylnaltrexone and morphine.

7. A method for treating a somatostatin related disease, comprising administering to a mammal in need thereof an effective amount of the compound represented by the general formula (I) according to claim 1 , a salt thereof, an N-oxide thereof, or a solvate thereof, wherein the somatostatin related disease is acromegaly.

Assignees

• Ono Pharmaceutical Co

Inventors

• Ishida Akiharu
• Matsushita Takeshi
• Sekiguchi Tetsuya
• Komagata Tatsuya
• Nishio Takuya

Classifications

• A61P5/06

  of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61K31/4418

  having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine · CPC title

• C07D211/58

  attached in position 4 · CPC title

• A61K31/455

  Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides · CPC title